Var2CSA DBL6-epsilon domain expressed in HEK293 induces limited cross-reactive and blocking antibodies to CSA binding parasites.
BACKGROUND
Pregnancy-associated malaria (PAM) is a serious consequence of Plasmodium falciparum-infected erythrocytes sequestration in the placenta through the adhesion to the placental receptor chondroitin sulfate A (CSA). Although women become resistant to PAM as they acquire transcending inhibitory immunity against CSA-binding parasites, hundreds of thousands of lives could be saved if a prophylactic vaccine targeting the surface proteins of placental parasites could be designed. Recent works point to the variant protein var2CSA as the key target for the development of a pregnancy-associated malaria vaccine. However, designing such a prophylactic vaccine has been hindered by the difficulty in identifying regions of var2CSA that could elicit broadly neutralizing and adhesion-blocking antibodies.


METHODS
Var2CSA is a very large protein with an estimated molecular weight of 350 kDa, and can be divided into six cysteine rich Duffy binding-like domains (DBL). The human embryonic kidney 293 cell line (HEK293) was used to produce secreted soluble recombinant forms of var2CSA DBL domains. The Escherichia coli expression system was also assessed for the domains not expressed or expressed in low amount in the HEK293 system. To investigate whether var2CSA binding DBL domains can induce biologically active antibodies recognizing the native var2CSA and blocking the interaction, mice were immunized with the refolded DBL3-X or the HEK293 secreted DBL6-epsilon domains.


RESULTS
Using the HEK293 expression system, DBL1-X, DBL4-epsilon and DBL6-epsilon were produced at relatively high levels in the culture supernatant, while DBL3-X and DBL5-epsilon were produced at much lower levels. DBL2-X and DBL3-X domains were obtained after refolding of the inclusion bodies produced in E. coli. Importantly, mice antisera raised against the recombinant DBL6-epsilon domain, specifically reacted against the surface of CSA-binding parasites and revealed adhesion blocking activity.


CONCLUSIONS
This is the first report showing inhibitory binding antibodies obtained through a var2CSA recombinant DBL domain immunization protocol. These results support the current strategies using var2CSA as immunogen in the aim of blocking placental sequestration of malaria parasites. This work is a step towards the development of a var2CSA based vaccine that will prevent pregnancy-associated malaria and improve pregnancy outcomes.
Fernandez
Pablo
P
Institut Pasteur, Unité de Biologie des Interactions Hôte-Parasite, CNRS URA2581, Batiment Nicolle, 25 rue du Docteur Roux, F-75724 Paris Cedex 15, France.
Viebig
Nicola K
NK
Dechavanne
Sébastien
S
Lépolard
Catherine
C
Gysin
Jürg
J
Scherf
Artur
A
Gamain
Benoit
B
D000818:Animals; D000913:Antibodies, Protozoan / Q000276:immunology*; D000953:Antigens, Protozoan / Q000235:genetics / Q000276:immunology*; D002448:Cell Adhesion / Q000276:immunology; D002460:Cell Line; D003429:Cross Reactions; D005260:Female; D006801:Humans; D008288:Malaria / Q000276:immunology / Q000517:prevention & control; D017780:Malaria Vaccines / Q000235:genetics / Q000276:immunology*; D051379:Mice; D008807:Mice, Inbred BALB C; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000276:immunology / Q000517:prevention & control; D017434:Protein Structure, Tertiary
D000913:Antibodies, Protozoan; D000953:Antigens, Protozoan; D017780:Malaria Vaccines; C512601:VAR2CSA protein, Plasmodium falciparum
Cell. 1995 Jul 14;82(1):77-87
7541722
Infect Immun. 2006 Jul;74(7):4357-60
16790811
Exp Parasitol. 2006 Feb;112(2):121-5
16274691
Nature. 1998 Oct 29;395(6705):851-2
9804416
Mol Microbiol. 2003 Jul;49(1):179-91
12823820
EMBO Rep. 2005 Aug;6(8):775-81
16025132
Cytometry. 1999 Apr 1;35(4):329-36
10213198
PLoS Med. 2006 Nov;3(11):e446
17105340
Placenta. 2004 May;25(5):359-78
15081631
J Immunol. 2000 Sep 15;165(6):3309-16
10975848
Infect Immun. 1999 Oct;67(10):5367-71
10496918
Am J Pathol. 1982 Dec;109(3):330-42
6758604
Mol Biochem Parasitol. 2006 Aug;148(2):117-24
16631964
Lancet. 2004 Jun 5;363(9424):1860-7
15183624
J Infect Dis. 1999 Aug;180(2):464-72
10395863
Exp Parasitol. 2005 Mar;109(3):195-7
15713452
J Immunol Methods. 1992 Jul 31;152(1):89-104
1640112
Int J Parasitol. 2007 Mar;37(3-4):273-83
17224156
Infect Immun. 2006 Aug;74(8):4875-83
16861676
Lancet. 2004 Jan 24;363(9405):283-9
14751701
J Infect Dis. 2005 Jul 15;192(2):331-5
15962229
Infect Immun. 2003 Nov;71(11):6620-3
14573685
Science. 1996 Jun 7;272(5267):1502-4
8633247
PLoS One. 2007 Sep 19;2(9):e910
17878945
Mol Med. 1997 Aug;3(8):508-18
9307979
J Infect Dis. 2006 Mar 1;193(5):713-20
16453268
J Exp Med. 2004 Nov 1;200(9):1197-203
15520249
Histopathology. 1993 Mar;22(3):211-8
8495954
J Infect Dis. 2005 Mar 15;191(6):1010-3
15717280
Science. 1976 Aug 20;193(4254):673-5
781840
Mol Biochem Parasitol. 2007 Oct;155(2):103-12
17669514
Cell. 1995 Jul 14;82(1):89-100
7606788